Loading…
Ken GriffinReduced
Citadel Advisors · Q2 2026
$2.79M
164.71K shares · 0.0% of portfolio
Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. (NTLA) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Cambridge, United States and has 377 employees. The company is worth $1.56B. Revenue was $67.67M in fiscal 2025, up 16.9% from the year before. It reported a net loss of $412.69M. The share price is 57.6% below its 52-week high of $26.35. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Two Sigma (Two Sigma Investments), at $88.58M. In that quarter, 4 of them opened or added to the position and 2 reduced it. Over the last 30 days, company insiders sold $23.17K of its stock on the open market and bought none.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -90.1% over 5Y.
today you would have $85.88▼ -91.4%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 10 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $8.99 | $11.66 | $30.49 | $34.89 | $118.24 | $54.40 | $14.67 | $13.65 | $19.22 | $13.11 | |
| P/S | 29.9x | 15.7x | 20.9x | 80.8x | 58.9x | 267.1x | 63.5x | 17.2x | 20.3x | 31.2x | 28.7x |
| P/B | 2.6x |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| GPCRStructure Therapeutics Inc. | $21.93 | — | 1.2x | 0.00% | -20.21% | $1.56B |
| RAREUltragenyx Pharmaceutical Inc. | $15.95 | — | — | 0.00% | — | $1.57B |
| GENBGenerate Biomedicines, Inc. | $12.09 | — | 3.4x | 0.00% | — | $1.55B |
| AZTAAzenta, Inc. | $36.01 |
| 1.6x |
| 1.4x |
| 2.8x |
| 2.5x |
| 8.5x |
| 7.0x |
| 2.7x |
| 2.2x |
| 2.7x |
| 2.3x |
| EPS | -$3.81 | -$5.25 | -$5.42 | -$6.16 | -$3.78 | -$2.40 | -$2.11 | -$1.98 | -$1.88 | -$1.42 |
| Profit margin | -710.17% | -609.85% | -896.77% | -1326.51% | -909.78% | -810.49% | -231.46% | -1100.12% | -280.42% | -258.62% | -191.97% |
| ROE | -34.54% | -61.47% | -59.52% | -45.82% | -38.38% | -25.75% | -25.47% | -175.70% | -30.71% | -22.47% | -15.08% |
Median of the years shown; P/E years above 200x are left out.
| — |
| 1.0x |
| 0.00% |
| -7.04% |
| $1.58B |
| CERTCertara, Inc. | $10.09 | — | 1.6x | 0.00% | -2.21% | $1.54B |
| MAZEMaze Therapeutics, Inc. | $27.53 | — | 3.4x | 0.00% | -37.35% | $1.53B |